【StemRim】Canada Patent Registration and Development of Heart Failure Treatment｜July 2026

Progress in Patent Registration and Pharmaceutical Development

StemRim has registered a patent in Canada for a new therapeutic drug using Ledasemide targeting cardiomyopathy, old myocardial infarction, and chronic heart failure caused by these conditions. This ensures expansion of application scope within North America and the potential for drug development. Currently, a Phase II physician-led clinical trial is underway at Osaka University Hospital targeting ischemic cardiomyopathy, with high expectations for future clinical development.

Future Outlook and Impact on Performance

This patent registration indicates progress in the research and development of the drug and application expansion, representing a significant step toward future clinical trials and commercialization. While no direct impact on the full-year earnings for July 2026 is anticipated, advancements in drug development may lead to future business expansion and revenue generation.